Sponsor Pipeline

Evopoint Biosciences Inc. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
10
Active Trials
6
Recruiting
1
Phase 3
6
Disease Areas
4
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-07-24 NCT06022757
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With…
critical Trial terminated
2026-07-24 NCT06022757
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With…
Enrollment reduced: 204 -> 12 participants
2026-07-24 NCT06022757
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With…
date change Primary completion moved earlier: 2028-08 -> 2025-01-13
2026-07-24 NCT06022757
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With…
date change Completion moved earlier: 2028-08 -> 2025-01-13
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-07-28 NCT07730515 Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated… Phase 1/2 Recruiting
2026-07-28 NCT07730580 Study of XNW5004 Tablets in Advanced Prostate Cancer Phase 2 Not Yet Recruiting
Active Trials by Phase
Phase 3
1
Phase 2
3
Phase 1/2
5
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06776952 A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients… Relapsed/Refractory Peripheral T Cell Lymphoma Recruiting
Phase 2
NCT07545603 Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular… Follicular Lymphoma, Grade 1 Recruiting
NCT06702605 To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell… Relapsed/Refractory Peripheral T Cell Lymphoma Not Yet Recruiting
NCT07730580 Study of XNW5004 Tablets in Advanced Prostate Cancer Advanced Prostate Cancer Not Yet Recruiting
Phase 1/2
NCT06702995 Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic… Metastatic Castrate-Resistant Prostate Cancer Recruiting
NCT06987500 A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed… Tumor, Solid Recruiting
NCT06799637 Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments Advanced Solid Tumors Recruiting
NCT07730515 Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated… Non-hodgkin Lymphoma Recruiting
NCT07327294 A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid… Advanced Solid Tumors Not Yet Recruiting
Phase 1
NCT07707674 Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic… Metastatic Pancreatic Cancer Not Yet Recruiting
Disease Areas
Get alerts when Evopoint Biosciences Inc.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free